Vaccitech PLC
F:2AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mugen Estate Co Ltd
TSE:3299
|
JP |
|
G
|
Graha Andrasentra Propertindo Tbk PT
IDX:JGLE
|
ID |
|
Nippon Air Conditioning Services Co Ltd
TSE:4658
|
JP |
|
D
|
Desun Real Estate Investment Services Group Co Ltd
HKEX:2270
|
CN |
|
iomart group PLC
LSE:IOM
|
UK |
|
Quantum Computing Inc
NASDAQ:QUBT
|
US |
|
K
|
Keep Inc
HKEX:3650
|
CN |
Vaccitech PLC
Total Current Liabilities
Vaccitech PLC
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaccitech PLC
F:2AB
|
Total Current Liabilities
$10m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Current Liabilities
$57m
|
CAGR 3-Years
2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Current Liabilities
£246.7m
|
CAGR 3-Years
44%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Current Liabilities
$247.8m
|
CAGR 3-Years
151%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Current Liabilities
£134.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Current Liabilities
£84.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
20%
|
|
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).
See Also
What is Vaccitech PLC's Total Current Liabilities?
Total Current Liabilities
10m
USD
Based on the financial report for Dec 31, 2025, Vaccitech PLC's Total Current Liabilities amounts to 10m USD.
What is Vaccitech PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
6%
Over the last year, the Total Current Liabilities growth was -36%. The average annual Total Current Liabilities growth rates for Vaccitech PLC have been -6% over the past three years , 6% over the past five years .
